Combination Cancer Therapy (Record no. 244156)

MARC details
000 -LEADER
fixed length control field 03656nam a22004695i 4500
001 - CONTROL NUMBER
control field 978-1-59259-864-9
003 - CONTROL NUMBER IDENTIFIER
control field DE-He213
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20160614135125.0
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION
fixed length control field cr nn 008mamaa
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 100301s2005 xxu| s |||| 0|eng d
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9781592598649
-- 978-1-59259-864-9
024 7# - OTHER STANDARD IDENTIFIER
Standard number or code 10.1385/1592598641
Source of number or code doi
049 ## - LOCAL HOLDINGS (OCLC)
Holding library Alfaisal Main Library
050 #4 - LIBRARY OF CONGRESS CALL NUMBER
Classification number RC254-282
072 #7 - SUBJECT CATEGORY CODE
Subject category code MJCL
Source bicssc
072 #7 - SUBJECT CATEGORY CODE
Subject category code MED062000
Source bisacsh
082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER
Classification number 616.994
Edition number 23
245 10 - TITLE STATEMENT
Title Combination Cancer Therapy
Medium [electronic resource] :
Remainder of title Modulators and Potentiators /
Statement of responsibility, etc edited by Gary K. Schwartz.
264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE STATEMENTS
Place of production, publication, distribution, manufacture Totowa, NJ :
Name of producer, publisher, distributor, manufacturer Humana Press,
Date of production, publication, distribution, manufacture 2005.
300 ## - PHYSICAL DESCRIPTION
Extent X, 284 p.
Other physical details online resource.
336 ## - CONTENT TYPE
Content Type Term text
Content Type Code txt
Source rdacontent
337 ## - MEDIA TYPE
Media Type Term computer
Media Type Code c
Source rdamedia
338 ## - CARRIER TYPE
Carrier Type Term online resource
Carrier Type Code cr
Source rdacarrier
347 ## -
-- text file
-- PDF
-- rda
490 1# - SERIES STATEMENT
Series statement Cancer Drug Discovery and Development
505 0# - FORMATTED CONTENTS NOTE
Formatted contents note Targeting of the EGFR As a Modulator of Cancer Chemotherapy -- Cyclin-Dependent Kinase Inhibitors in Combination Chemotherapy -- Development of Protein Kinase C and Cyclin-Dependent Kinase Inhibitors As Potentiators of Cytotoxic Drug Action in Leukemia -- Carboxyamidotriazole, an Inhibitor of Nonvoltage-Operated Calcium Entry -- Targeted ?-Particle Therapy -- Pharmacological Modulation of Fluoropyrimidines -- Development of Inhibitors of HER2 With Taxanes -- Targeting NF-?B to Increase the Activity of Cisplatin in Solid Tumors -- Combinations of Chemotherapy and G3139, an Antisense Bcl-2 Oligonucleotide -- Use of Animal Models to Evaluate Signal Transduction Inhibitors As Modulators of Cytotoxic Therapy.
520 ## - SUMMARY, ETC.
Summary, etc Early clinical trials of the new molecular-based anticancer agents have shown that many are marginal in controlling cancer, but prove to be potent modulators and potentiators of chemotherapy-induced apoptosis when used in combination with classic cytotoxic drugs or radiation. In Combination Cancer Therapy: Modulators and Potentiators, expert physician-scientists and clinicians with first-hand experience in the clinical development of targeted therapies review those combinations that hold the most promise for the future of medical oncology, detailing their optimal sequence, pharmacokinetic interactions, and interaction with downstream cellular signals. The combinations run the gamut of targeted therapies against cell surface receptors (EGF-R and HER2), the cell cycle (the CDKs), signal transduction events (PKC and NF-kB), apoptosis (bcl-2), as well as focused therapies in ovarian cancer, hematologic diseases, and breast cancer. The authors emphasize novel translational approaches that are rapidly moving from the laboratory benchtop to the patient's bedside as a new generation of cancer therapeutics. Cutting-edge and forward-looking, Combination Cancer Therapy: Modulators and Potentiators offers everyone in the fields of cancer drug development and therapy a powerful new understanding of the optimal sequencing and scheduling of new combination drug therapies necessary to maximize the effects for cancer patients today.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Medicine.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Oncology.
650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Medicine & Public Health.
650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Oncology.
655 #7 - INDEX TERM--GENRE/FORM
Genre/form data or focus term Electronic books.
Source of term local
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Schwartz, Gary K.
Relator term editor.
710 2# - ADDED ENTRY--CORPORATE NAME
Corporate name or jurisdiction name as entry element SpringerLink (Online service)
773 0# - HOST ITEM ENTRY
Title Springer eBooks
776 08 - ADDITIONAL PHYSICAL FORM ENTRY
Display text Printed edition:
International Standard Book Number 9781588292001
830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE
Uniform title Cancer Drug Discovery and Development
856 40 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="http://ezproxy.alfaisal.edu/login?url=http://dx.doi.org/10.1385/1592598641">http://ezproxy.alfaisal.edu/login?url=http://dx.doi.org/10.1385/1592598641</a>
912 ## -
-- ZDB-2-SME
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Source of classification or shelving scheme Library of Congress Classification
Koha item type eBooks

No items available.

Copyright © 2020 Alfaisal University Library. All Rights Reserved.
Tel: +966 11 2158948 Fax: +966 11 2157910 Email:
librarian@alfaisal.edu